Search results for "Neuroprotective agent"

showing 10 items of 156 documents

Daidzein has neuroprotective effects through ligand-binding-independent PPARγ activation.

2011

Phytoestrogens are a group of plant-derived compounds that include mainly isoflavones like daidzein. Phytoestrogens prevent neuronal damage and improve outcome in experimental stroke; however, the mechanisms of this neuroprotective action have not been fully elucidated. In this context, it has been postulated that phytoestrogens might activate the peroxisome proliferator-activated receptor-γ (PPARγ), which exerts neuroprotective effects in several settings. The aim of this study was to determine whether the phytoestrogen daidzein elicits beneficial actions in neuronal cells by mechanisms involving activation of PPARγ. Our results show that daidzein (0.05-5 μM) decreases cell death induced b…

endocrine systemmedicine.drug_classPyridinesPeroxisome proliferator-activated receptorPharmacologyLigandsNeuroprotectionCellular and Molecular Neurosciencechemistry.chemical_compoundmedicineSynaptic vesicle recyclingAnimalsReceptorCells Culturedchemistry.chemical_classificationNeuronsDaidzeinfood and beveragesCell BiologyIsoflavonesReceptor antagonistIsoflavonesRatsOxygenPPAR gammaGlucoseNeuroprotective AgentschemistryBenzamidesPhytoestrogensNeurochemistry international
researchProduct

Expression and regulation of mPer1 in immortalized GnRH neurons.

2003

Hypothalamic GnRH (gonadotropin-releasing hormone) neurons play a critical role in the initiation and maintenance of reproduction competence. Using the mouse GnRH neuronal cell line, GT1-7, we have characterized the expression of the gene mPer1, a recognized key element of the mammalian circadian clockwork. Both mPer1 transcripts and the 136 kDa mPER1 gene product could be detected in these cells. Immunocytochemical analysis also confirmed expression of mPER1 both in vitro and in vivo in GnRH neurons. Activation of cyclic AMP signalling pathways in vitro elevated GnRH secretion as well as mPer1 expression and nuclear mPER1 immunoreactivity. As mPER1 is known to feedback on transcriptional a…

endocrine systemmedicine.medical_specialtyCellImmunoblottingCell Cycle ProteinsBiologyGene productGonadotropin-Releasing HormoneMiceInternal medicineGene expressionmedicineAnimalsGeneCells CulturedRegulation of gene expressionNeuronsReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceColforsinNuclear ProteinsPeriod Circadian ProteinsImmunohistochemistryPreoptic AreaIn vitromedicine.anatomical_structureEndocrinologyNeuroprotective AgentsGene Expression RegulationCell cultureHypothalamushormones hormone substitutes and hormone antagonistsVasoactive Intestinal PeptideNeuroreport
researchProduct

EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.

2005

Leukocytes contribute to the ischemia-reperfusion injury. Recent studies suggested endothelins could be important mediators for leukocyte activation in stroke. We tested if the endothelinA receptor antagonist BSF-208075 (ambrisentan) could reduce an ischemic lesion by modulation of leukocyte-endothelium interactions. Twenty-four gerbils underwent either a sham operation (n=6) or 15 min of bilateral carotid artery occlusion resulting in global cerebral ischemia. Ischemic animals received normal saline (n=6), 5 mg/kg BSF-208075 (n=6) or 30 mg/kg (n=6) administered intravenously at 10 min of reperfusion. Leukocytes rolling or adhering to endothelium were counted by intravital microscopy in par…

medicine.hormoneMaleAmbrisentanmedicine.drug_classEndothelin A Receptor AntagonistsIschemiaPharmacologyBrain IschemiaEndothelinsLeukocytesMedicineAnimalsImmunologic FactorsMolecular BiologyStrokeDose-Response Relationship DrugPhenylpropionatesbusiness.industryGeneral NeuroscienceEndothelinsAntagonistBrainmedicine.diseaseReceptor antagonistReceptor Endothelin APyridazinesStrokeChemotaxis LeukocyteNeuroprotective AgentsTreatment OutcomeAnesthesiaCerebrovascular CirculationReperfusion InjuryNerve DegenerationEncephalitisNeurology (clinical)businessEndothelin receptorGerbillinaeIntravital microscopyDevelopmental Biologymedicine.drugBrain research
researchProduct

Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms.

2014

Postmenopausal women may be more vulnerable to cognitive loss and Alzheimer's disease (AD) than premenopausal women because of their deficiency in estrogens, in addition to their usually older age. Aerobic physical exercise has been proposed as a therapeutic approach for maintaining health and well-being in postmenopausal women, and for improving brain health and plasticity in populations at high risk for AD. To study the neuroprotective mechanisms of physical exercise in a postmenopausal animal model, we submitted previously ovariectomized, six-month old non-transgenic and 3xTg-AD mice to three months of voluntary exercise in a running wheel. At nine months of age, we observed lower grip s…

medicine.medical_specialtyBehavioral testsEndocrinology Diabetes and MetabolismOvariectomyP-CREBPhysical exerciseMice Transgenictau ProteinsCREBNeuroprotectionGrip strengthAmyloid beta-Protein PrecursorMiceEndocrinologyCognitionAlzheimer DiseaseInternal medicinePhysical Conditioning AnimalNeuroplasticitymedicinePresenilin-1DementiaAnimalsApathy3xTg-AD miceBiological PsychiatryNeuronsFrailtybiologyEndocrine and Autonomic SystemsBrain-Derived Neurotrophic FactorPhysical exerciseAlzheimer's diseaseCatalasemedicine.diseaseMice Inbred C57BLPsychiatry and Mental healthDisease Models AnimalBDNFEndocrinologyNeuroprotective AgentsCytoprotectionbiology.proteinOvariectomized ratFemalemedicine.symptomPsychologySignal TransductionPsychoneuroendocrinology
researchProduct

Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon

2015

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. It is estimated that each year TBIs are associated with 1.1 million emergency department visits, 235,000 hospitalizations, and 50,000 deaths (1). Despite improvements in medical interventions, there are still no neuroprotective agents available to counteract secondary or delayed damage to the traumatically injured human brain or to promote its repair. TBI encompasses heterogeneous etiologic, anatomical, and molecular patterns of injury that exhibit different propensities to cause cerebral damage. Without careful consideration of individual injuries, the results of therapeutic trials remain difficu…

medicine.medical_specialtyClinical Trials as Topicbusiness.industryTraumatic brain injurySettore MED/27 - NeurochirurgiaMedicine (all)Neuroprotective AgentRecombinant Proteinmedicine.diseaseRecombinant ProteinsEpoetin AlfaNeuroprotective AgentsErythropoietinBrain InjuriesBrain InjurieReceptors ErythropoietinMedicineHumansSurgeryNeurology (clinical)businessIntensive care medicineErythropoietinmedicine.drugHuman
researchProduct

Will it ever become possible to prevent dopaminergic neuronal degeneration?

2008

Parkinsons disease (PD) is the second leading age-related degenerative brain disease in the world affecting millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at present no cure for it. Furthermore, there are no proven therapies for prevention of PD and alth…

medicine.medical_specialtyDopaminePopulationNeurological disorderDiseaseNeuroprotectionSettore BIO/09 - FisiologiaNeuroprotective agentsRisk FactorsmedicineAnimalsHumansNeuronal degenerationNeurodegeneration Neuroprotection Parkinson's diseaseIntensive care medicineeducationPharmacologyNeuronseducation.field_of_studyCell Deathbusiness.industryGeneral NeuroscienceDopaminergicNeurodegenerative DiseasesParkinson's disease -- Treatmentmedicine.diseaseBrain diseaseNeuroprotective AgentsDrug developmentbusinessNervous system -- Degeneration
researchProduct

Neuroprotective Actions of Estradiol and Novel Estrogen Analogs in Ischemia: Translational Implications

2010

This review highlights our investigations into the neuroprotective efficacy of estradiol and other estrogenic agents in a clinically relevant animal model of transient global ischemia, which causes selective, delayed death of hippocampal CA1 neurons and associated cognitive deficits. We find that estradiol rescues a significant number of CA1 pyramidal neurons that would otherwise die in response to global ischemia, and this is true when hormone is provided as a long-term pretreatment at physiological doses or as an acute treatment at the time of reperfusion. In addition to enhancing neuronal survival, both forms of estradiol treatment induce measurable cognitive benefit in young animals. Mo…

medicine.medical_specialtyGPR30hippocampusIschemiaEstrogen receptorHippocampusNeuroprotectionArticleEstradiol CongenersIschemiaInternal medicineestradiolmedicineAnimalsHumansEndocrine and Autonomic Systemsbusiness.industryCREBEstrogen analogapoptosismedicine.diseasestrokeglobal ischemiainsulin-like growth factor-1EndocrinologyNeuroprotective AgentsneuroprotectionEstradiol CongenersbusinessGPERhormones hormone substitutes and hormone antagonistsHormoneestrogen receptor
researchProduct

Soy-derived phytoestrogens as preventive and acute neuroprotectors in experimental ischemic stroke: Influence of rat strain

2011

The ability of a soy-based high-phytoestrogen diet (nutritional intervention) or genistein (pharmacological intervention), to limit ischemic brain damage in Wistar, Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats, has been assessed. As to the nutritional intervention, two groups from each strain received either a phytoestrogen-free (PE-0) or a high-phytoestrogen (PE-600) diet from weaning to adulthood. As to the pharmacological intervention, all animals were fed the standard soy-free AIN-93G diet and subsequently separated into two groups from each strain to receive either pure genistein (aglycone form, 1mg/kg/day intraperitoneal) or vehicle at 30 min reperfusion. After an epis…

medicine.medical_specialtyIschemiaPharmaceutical ScienceGenisteinBlood PressurePhytoestrogensBrain IschemiaBrain ischemiachemistry.chemical_compoundInternal medicineDrug DiscoveryAnimalsMedicineWeaningcardiovascular diseasesPharmacologyPlant Extractsbusiness.industryRats Inbred StrainsCerebral InfarctionIsoflavonesmedicine.diseaseGenisteinRatsStrokeNeuroprotective AgentsEndocrinologyBlood pressureComplementary and alternative medicinechemistryReperfusion InjuryMolecular MedicinePhytoestrogensSoybeansbusinessReperfusion injuryPhytotherapyPhytomedicine
researchProduct

Practical importance of neuroprotection in Parkinson's disease.

2003

Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeu…

medicine.medical_specialtyNeurologyParkinson's diseaseIndolesBioinformaticsNeuroprotectionAntiparkinson AgentsDegenerative diseaseSelegilineAmantadineMedicineHumansbusiness.industrySelegilineAmantadineParkinson Diseasemedicine.diseaseClinical trialRopiniroleNeuroprotective AgentsNeurologyDopamine AgonistsNeurology (clinical)businessNeurosciencemedicine.drugJournal of neurology
researchProduct

Oxygen and glucose deprivation induces major dysfunction in the somatosensory cortex of the newborn rat

2005

The mechanisms and functional consequences of ischemia-induced injury during perinatal development are poorly understood. Subplate neurons (SPn) play a central role in early cortical development and a pathophysiological impairment of these neurons may have long-term detrimental effects on cortical function. The acute and long-term consequences of combined oxygen and glucose deprivation (OGD) were investigated in SPn and compared with OGD-induced dysfunction of immature layer V pyramidal cortical neurons (PCn) in somatosensory cortical slices from postnatal day (P)0-4 rats. OGD for 50 min followed by a 10-24-h period of normal oxygenation and glucose supply in vitro or in culture led to pron…

medicine.medical_specialtyPatch-Clamp TechniquesTolbutamideIn Vitro TechniquesBiologySomatosensory systemMembrane PotentialsInternal medicineSubplatemedicineExtracellularAnimalsHypoglycemic AgentsMagnesiumEnzyme InhibitorsHypoxiaOuabainNeuronsMembrane potentialCaspase 3General NeuroscienceDose-Response Relationship RadiationDepolarizationSomatosensory CortexHyperpolarization (biology)ImmunohistochemistryElectric StimulationRatsGlucoseNeuroprotective AgentsEndocrinologymedicine.anatomical_structureAnimals Newbornnervous systemApoptosisCaspasesNMDA receptorDizocilpine MaleateEuropean Journal of Neuroscience
researchProduct